Skip to Main Content

dementia

Dementia is the broad term for a decline in cognitive function that affects memory, thinking, and behavior. Alzheimer’s disease is a form of dementia, and stories here track the latest dementia research and dementia treatments.

Articles include a look at the new Alzheimer’s drug Leqembi, the link between air pollution and dementia risk, and a new field of Alzheimer’s research involving CRISPR technologies.

Latest

Biotech Andrew Joseph

STAT Plus: U.K.’s cost-effectiveness agency gives negative review of Alzheimer’s drug Leqembi

First Opinion Mike Zuendel

Phasing out the ‘D-word’

Health Rohan Rajeev

Vision loss and high cholesterol identified as risk factors for dementia

In the Lab Associated Press

Blood tests for Alzheimer’s diagnosis were 91% accurate in new study

Biotech Andrew Joseph

STAT Plus: European regulators say Alzheimer’s therapy Leqembi should be rejected

First Opinion Lawrence K. Altman

President Biden needs a full medical evaluation. Voters deserve to know the results

Biotech Elaine Chen and Matthew Herper

STAT Plus: FDA approves Eli Lilly’s early Alzheimer’s treatment

In the Lab Rohan Rajeev

Protein maps in cerebrospinal fluid offer insight into Alzheimer’s biology

All Coverage

Health Annalisa Merelli

World Trade Center responders exposed to more dust saw higher risk of early dementia

Biotech Matthew Herper and Elaine Chen

STAT Plus: FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted to a smaller group

advertisement

First Opinion Carolyn Clevenger

Outdated Medicare rules prevent some dementia patients from getting the medications they need

Biotech Matthew Herper

STAT Plus: Getting Alzheimer’s treatment to those who need it poses particular challenges

STAT Events Megan Molteni

STAT Virtual Event | Navigating a New Era in Alzheimer’s Treatment

Health Jonathan Wosen

STAT Plus: Alzheimer’s risk gene APOE4 may cause a distinct form of the disease, study suggests

First Opinion Katherine O'Malley

Primary care physicians should be at the heart of treating Alzheimer’s

Biotech Andrew Joseph

STAT Plus: In surprise move, FDA calls for advisory committee on Lilly’s Alzheimer’s drug

First Opinion Lawrence K. Altman

STAT Plus: I’ve reported on the health of every president since Reagan. Here’s what I think about Trump and Biden

Biotech Jonathan Saltzman — Boston Globe

STAT Plus: Biogen Alzheimer’s drug launch off to slow start

Letters to the editor Torie Bosch

What STAT readers think about Aduhelm, CTE and the Super Bowl, and more

Health Annalisa Merelli

A neuropsychologist clarifies science on aging and memory in wake of Biden special counsel report

First Opinion Jason Karlawish

STAT Plus: Aduhelm was a mess — and it could happen again

Biotech Damian Garde, Adam Feuerstein, and Allison DeAngelis

STAT Plus: The lessons of Aduhelm, Biogen’s Alzheimer’s drug that was not to be

Health Isabella Cueto

Some dementia patients might have reversible symptoms caused by cirrhosis, study says

Biotech Damian Garde

STAT Plus: Years after a polarizing approval, Biogen walks away from Aduhelm

In the Lab Andrew Joseph

Scientists document first-ever transmitted Alzheimer’s cases, tied to no-longer-used medical procedure

Health tech Mario Aguilar

STAT Plus: Cognito raises $35 million for Alzheimer’s treatment device, touts benefits compared to drugs

Letters to the editor Torie Bosch

STAT readers on patient advocacy, the utility of diagnostic tests, and more

The Readout Meghana Keshavan

STAT Plus: Today’s biotech news roundup, in under 800 words

First Opinion Madhav Thambisetty

Manufacturers need to be more open about a dangerous Alzheimer’s drug side effect